Archives for May 2021

Ontario Agriculture & Agri-Food Sector to Benefit from Provincial Investment

May 3, 2021 – The Government of Ontario and other partners are investing nearly $27 million into five Ontario Genomics-led and co-led projects in the Large Scale Applied Research Program (LSARP) with applications in the agriculture and agri-food sector. This Genome Canada program supports large-scale genomics applied research projects using genomics approaches to address challenges in Canada’s key economic sectors and create socio-economic benefits for Canada. The provincial government invested over $4 million with additional funding from Genome Canada ($9.7 million) and industry and research partners for a total of $27 million in support for these job-creating projects.

Ontario Genomics plays a vital role in advancing these projects by supporting the development of their proposals, helping them access diverse funding sources, and finding the right industry partners to take this research out of the lab to apply it to the world’s most pressing challenges. Since its inception in 2000, Ontario Genomics has raised more than $1.27 billion for genomics applied research in Ontario and directly supported more than 9,100 trainees and jobs. We have 110+ active projects, 500+ impactful partnerships and have secured $1.34 billion in follow-on investments.

Ontario’s agriculture and agri-food sector supports one in eight Ontario jobs and accounts for over 30% of Canada’s total GDP.

“While Ontario’s agriculture and agri-food sector is strong and growing, its demands and challenges are also rising. Global food insecurity, competition, and technological disruptions are on the rise because of epidemics, climate change, and economic constraints. Fortunately, genomics-based innovations and technologies provide significant opportunities to advance and modernize Ontario’s agriculture and agri-food sector for a critical competitive advantage.” – Dr. Bettina Hamelin, President and CEO, Ontario Genomics.

“As we recover from the COVID-19 pandemic, our government is committed to investing in projects that support research and innovation in the agri-food and agriculture sectors. By investing in projects supported by Ontario Genomics, our government is supporting research and technological advances in the sector to ensure the sustainability of the agriculture and agri-food sectors.” – Ross Romano, Ontario’s Minister of Colleges and Universities.

One of the projects funded in this round, the “GEN-FISH” project, led out of the University of Windsor, is using genomic approaches to develop toolkits based on so-called environmental DNA (eDNA) from water samples that will provide quantitative assessments of the health of fish and the stressors they face. Collectively, these toolkits will enable a complete and accurate assessment of the status of Canada’s freshwater fish resources. This will save millions of dollars in fish survey costs and will result in additional indirect savings through more effective and directed management action. Furthermore, and most importantly, this project will ensure the sustainability of Canada’s freshwater fish resources for generations to come. This project has already piqued the interest of numerous industries in the environmental sector.

“Despite freshwater fishes being critical for Ontario’s economy, food security and aquatic ecosystem health, over 25% of its freshwater fish species are considered “at risk.” The Genomic Network for Fish Identification, Stress and Health (GEN-FISH) brings together 25 experts from across Canada to address the startling loss of fish biodiversity using genomic tools integrated with cutting-edge social science methods. Our work will help stakeholders effectively conserve and manage fish stocks through assessment of fish community composition and health, facilitated by extensive collaboration and consultation with fishery professionals.” – Dr. Daniel Heath, Project Lead & Professor, University of Windsor.

“The project strives to enhance local capacity by supporting traditional ecological knowledge preservation and inclusion to ensure outcomes address local research priorities, specifically food security and subsistence fisheries, and potential opportunities for sustainable economic development options. FISHES will work closely together with traditional knowledge holders and scientists, local and regional governments, Ministère des Forêts, de la Faune et des Parcs and Fisheries and Oceans Canada on seven species of fish across the North (including Northern Ontario) to establish new methods for stock identification and delineation of mixed stocks to enhance sustainable co-management for communities.” – Dr. Stephan Schott, Project Co-Lead & Associate Professor, Carleton University.

Another project that has been funded, aims to use genomic tools to develop BeeCSI – a new health assessment and diagnosis platform powered by stressor-specific markers. “Our Ontario and Genome Canada funded project will help us develop tools that beekeepers can use to understand the stressors affecting their colonies. This will be of great benefit to beekeepers who are losing a large number of their colonies every winter to unknown causes. The funding is also very timely as COVID-19 has hit beekeepers particularly hard.” – Dr. Amro Zayed, Project Lead & Professor, York University.

Our 4DWheat project is important because wheat alone provides 20% of the proteins and 20% of the calories of the world’s population. Canada is one of the largest wheat exporters of the world. With 1 million acres planted to wheat in Ontario and a farm-gate value of $440 million, Ontario is incontestably an important contributor. “This is why Canada, and Ontario, feed the world. However, in order to continue to be the leader that we are, we must address the yield gap. Indeed, there is a disparity between population growth and food production prediction for the next 30 years. To address such gap, 4DWheat is exploring the potential to improve wheat by accessing genetic diversity from wild relatives. 4DWheat is a ‘thinking outside the box’ project that aims to harness Diversity, advance Domestication, enable Discovery and expedite Delivery.” – Dr. Sylvie Cloutier, Agriculture & Agri-Food Canada (AAFC) Co-lead of the 4DWheat project.

The dairy cattle resilience project led by Dr. Christine Baes is making strides in the agri-food industry. “The Resilient Dairy Genome Project addresses a number of important issues related to human and animal health, environmental impacts, sustainability and social acceptability, while responding to the growing need for safe, affordable, nutritious and high-quality protein. The genetic selection index for resilience under development will allow more accurate selection for fertile, disease resilient and environmental efficient animals. This approach will result in wider benefits to Canadian society, like reduced reliance on antibiotics, better animal welfare, reduced methane emissions and reduced land required for feed production. The strong partnership between academia and industry, including over 40 national and international partners, will ensure the collection of new data, and broad application of project outputs for the benefit of Canadian and global food security and sustainability.” – Dr. Christine Baes, Project Lead & Associate Profession, University of Guelph.


Learn more about these five funded LSARP projects:

Major Investment in Genomics Research and Industry to Improve Ontario Healthcare and Environment

May 3, 2021 – The Government of Ontario is investing nearly $3 million in three Ontario Genomics-led projects as part of the Genomic Applications Partnership Program (GAPP). This program funds industry-partnered projects that use genomics tools and technologies to address real-world challenges and opportunities with the intent to create numerous downstream impacts for Ontario, such as job creation and revenue generation. Additional funding from Genome Canada ($4.2 million), industry and research partners brings the total investment into these projects to $13 million.

Ontario is a world leader in genomics research, producing breakthroughs in science and transforming our understanding of the world around us. Genomics technologies and applied research are already being used to tackle important challenges and develop innovative solutions across diverse sectors of the economy, including human health and the environment.

Ontario Genomics plays a vital role in advancing these projects by supporting the development of their proposals, helping them access diverse funding sources, and finding the right industry partners to take this research out of the lab to apply it to the world’s most pressing challenges. Since its inception in 2000, Ontario Genomics has raised more than $1.27 billion for genomics applied research in Ontario and directly supported more than 9,100 trainees and jobs. We have 110+ active projects, 500+ impactful partnerships and have secured $1.34 billion in follow-on investments.

This investment will support researchers at the University of Toronto and The Hospital for Sick Children. In collaboration with industry partners, including Bright Angel Therapeutics and Nanostring, these genomics-based projects will have real, positive impacts on our healthcare system, as well as the environment and well-being of Canadians.

“Partnerships between the researchers and industry are the cornerstone of Ontario’s thriving innovation community. By supporting the development and uptake of new technologies that provide game-changing solutions to the world’s most pressing challenges, Ontario Genomics is helping to nurture healthy people, a healthy economy, and a healthy planet for generations to come.” – Dr. Bettina Hamelin, President and CEO, Ontario Genomics

“Our government is dedicated to improving the health and wellbeing of Ontarians. By investing in Ontario Genomics, we’re supporting significant advancements in research and innovation in the healthcare sector to ensure Ontarians have access to state-of-the-art healthcare services and technologies. These projects aren’t only aimed at improving the healthcare and wellbeing of Ontarians, but also putting Ontario on the map as a global leader in research and innovation in the healthcare sector. ”- Ross Romano, Ontario’s Minister of Colleges and Universities.

“With GAPP funding, in partnership with NanoString and SickKids, we are excited to be developing a novel diagnostic test that will allow us to uncover the molecular pathways that are driving each patient’s cancer. This test is the first of its kind and will help us to optimize targeted therapy for cancer patients from across Ontario,” said Dr. Cynthia Hawkins, Project Lead & Neuropathologist, The Hospital for Sick Children.

“SickKids is pioneering the development of diagnostics that utilize both protein and mRNA biomarkers to identify patients who will respond to targeted therapies. Their selection of nCounter® as the platform of choice for this effort shows its unique potential to gather meaningful, high-quality multi-modal data to advance precision medicine for kids with cancer,” said Sean Ferree, Vice President of Customer Experience, NanoString. “It\’s an honour to receive GAPP support and to work together to better understand the characteristics that make treatments effective.”

“Bright Angel Therapeutics is very grateful for the support from Ontario Genomics in securing the GAPP investment.   The partnership with the University of Toronto gives the company access to state-of-the-art genomic tools, expertise and resources to assist us in advancing our lead antifungal drug development program from the bench to the bedside.  Government investments, such as this one, provide vital resources to early-stage companies that enable them to build out their technology platforms, position themselves for subsequent private investment rounds and build out the innovation ecosystem.” – Dr. Dominic Jaikaran, President & CEO Bright Angel Therapeutics

“This investment will catalyze the translation of genomics-driven fundamental science focused on discovery of vulnerabilities in fungal pathogens into new strategies to overcome drug resistance and treat life-threatening fungal infectious disease.” – Dr. Leah Cowen, Associate Vice President, Research, University of Toronto.


Learn more about the three funded GAPP projects:

  • Targeting fungal stress responses to provide first-in-class treatment for drug-resistant fungal pathogens (Receptor – Bright Angel Therapeutics): This project will develop a novel anti-fungal drug that will tackle drug resistance at its root. This new treatment option would help fill an urgent, unmet clinical need, reduce morbidity and mortality caused by fungal infections, and provide significant savings to the Canadian healthcare system, which currently spends $345 million on treating invasive fungal infections.
  • Field Validation of Technologies for Anaerobic Benzene and Alkylbenzene Bioremediation (Receptor – SiREM): This project aims to demonstrate the efficacy of a broad set of novel and specialized anaerobic bioaugmentation cultures in pilot trials at three different benzene contaminated sites. The team will use metagenome-enabled analysis, groundwater modelling, and tracking of the microbial populations and functional genes to improve overall remediation outcomes and restore ecosystem health.
  • NanoString nCounter® Vantage 3D platform-based complementary diagnostic tests for precision medicine in pediatric cancers (Receptors – The Hospital for Sick Children and Nanostring): To best guide therapeutic choices, this project aims to amalgamate proteomic data with genomic and transcriptomic information to create laboratory-developed (LDT)-complementary diagnostics for the most common pediatric cancers. Additionally, this project has international (NanoString) and Ontario-based (SickKids) co-receptors deriving benefits from this diagnostic technology. 

Breakthrough Ontario Projects Receive Over $28 Million to Advance Genomics Innovations

May 3, 2021 – The Government of Ontario is investing over $5.7 million in eleven Ontario Genomics-led projects as part of the Bioinformatics and Computational Biology (B/CB) Competition and the Disruptive Innovations in Genomics (DIG) Funding Competition. These programs aim to support transformative, made-in-Ontario genomics technological development to improve human health, agriculture, and natural resources for social and economic benefits for Canada. Additional funding from Genome Canada (over $10 million) and industry and research partners provide a total of $28 million to support these impactful and innovative projects.

Ontario Genomics plays a vital role in advancing these projects by supporting the development of their proposals, helping them access diverse funding sources, and finding the right industry partners to take this research out of the lab to apply it to the world’s most pressing challenges. Since its inception in 2000, Ontario Genomics has raised more than $1.27 billion for genomics applied research in Ontario and directly supported more than 9,100 trainees and jobs. We have 110+ active projects, 500+ impactful partnerships and have secured $1.34 billion in follow-on investments.

“This funding takes these projects to the next level,” says Dr. Bettina Hamelin, President and CEO, Ontario Genomics. “By tackling important challenges and developing innovative solutions across diverse sectors of the economy, we ensure Ontario has a thriving innovation and research community and made-in-Ontario genomics tools and technologies.”

“The Ontario government is committed to supporting “Ontario made” innovations, ideas and products. As our government continues to focus on recovering from the economic impacts of COVID-19, we’re proud to support Ontario Genomics as they fund research and innovation projects that can improve human health and wellbeing, agriculture and natural resources. By investing in these projects now, our government is supporting ideas that will have significant social and economic benefits for the province in the future.” – Ross Romano, Ontario’s Minister of Colleges and Universities.

“We are thrilled to be working with the government of Ontario and Ontario Genomics to develop a truly disruptive technique for non-invasive prenatal diagnostics.” – Dr. Aaron Wheeler, Project Lead & Professor, University of Toronto.

The SYNERGxDB web application, whose development was supported by Ontario Genomics, will enable researchers to efficiently mine the large-space of drug combinations, speeding up the development of new therapeutic strategies that are much needed for aggressive cancer types. SYNERGxDB provides researchers with easy access to data that have been curated, annotated and processed using the best standards in the field. This rich resource will continue to grow as new data are released and integrated, supporting the future of cancer research.” – Dr. Benjamin Haibe-Kains, Project Lead, Princess Margaret Cancer Centre.


Here are snippets of three of the eleven funded projects:

  • SYNERGx: a computational framework for drug combination synergy prediction: This project is developing SYNERGx, a new computational platform that will integrate multiple pharmacogenomic datasets. The platform will implement analytic tools to improve modelling of synergistic drug effects. SYNERGx will provide an efficient way to design new therapeutic strategies to treat cancer.
  • CReSCENT: CanceR Single Cell ExpressioN Toolkit: This project aims to develop CReSCENT, a scalable and standardized set of novel algorithmic methods and tools, deployed on cloud computing infrastructure, to allow comparison of cells in cancerous and healthy tissues. CReSCENT will bring together researchers across a broad spectrum of scientific areas and disease types. In the long term, this system will pave the way for novel single-cell diagnostics and the discovery of new drug strategies for improved health care.
  • Development of a digital microfluidic platform to identify and target single cells from a heterogeneous cell population for lysis in an ultra-low volume for non-invasive prenatal diagnosis: This project is using a digital microfluidics and genomic analysis platform to provide a safe, non-invasive, and inexpensive prenatal diagnostic test. With no other test like it available, it will compete in the multi-million-dollar global market and save the healthcare system hundreds of millions of dollars. The technique will be commercialized through a start-up company that will attract investment and create job opportunities in Canada’s burgeoning high-tech/biotech sector.

Congratulations to all 11 projects on successful proposals to the Government of Ontario to continue promising applied research that leads to novel solutions.

Learn more about the funded B/CB projects:

Learn more about the funded DIG projects: